Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Home
Ekf Diagnostics Holdings Plc
Notice of interim results
Published Sep 10 2025
5 min read

Notice of interim results

 

EKF Diagnostics Holdings plc

("EKF" or the "Company", or the "Group")

 

Notice of interim results

Investor presentation

                                                                                                                                                             

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, confirms it will announce its interim results for the six months ended 30 June 2025 on Tuesday 16 September.  

 

Investor Presentation

EKF Diagnostics will be hosting a live online presentation open to all existing and potential investors on Tuesday 16 September 2025 at 10.30am (BST), via the Investor Meet Company platform. Investors can sign up to Investor Meet Company for free and add to meet EKF Diagnostics via:

 

https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor

 

Investors who already follow EKF on the Investor Meet Company platform will automatically be invited.

 

A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

 via Walbrook PR

Gavin Jones, Chief Executive Officer

 

Stephen Young, Chief Financial Officer

 


Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Phil Davies / Oliver Platts




Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings 

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

A white machine and a blue device Description automatically generated

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

Point-of-Care analysers in the key areas of Hematology and Diabetes 

Life Sciences offers contract fermentation services for clinically important enzymes and proteins, and the manufacture of Beta-Hydroxybutyrate (β-HB), used as a quantitative ketone test to identify patients suffering from diabetic ketoacidosis, as well as in many other clinical applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.